PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Nat Genet. Author manuscript; available in PMC 2011 May 3.
Published in final edited form as:
PMCID: PMC3086200
NIHMSID: NIHMS279601

Variation in KLK Genes, Prostate Specific Antigen, and Risk of Prostate Cancer

Genome-wide association studies have identified SNPs associated with prostate cancer. Recently, SNPs in KLK3 were related to prostate cancer risk in a genome-wide association study (GWAS; 1,854 cases)1 and two candidate gene investigations (596 and 209 cases, respectively)2,3, raising the possibility that this gene and its encoded protein PSA (prostate specific antigen; kallikrein-related peptidase), which is widely-used as a biomarker for prostate cancer detection, are etiologically related to this disease.

Understanding the contribution of common genetic variation in KLK3 to prostate cancer risk is daunting because SNPs in KLK3 are determinants of serum PSA concentrations1,2,4, and thus, observed risk relationships could be due to differential identification of cases, in settings where PSA is used in screening or clinical diagnosis of this disease. Therefore, we evaluated the association of 24 tagSNPs in the KLK region (including KLK3 and nearby genes KLK1, KLK2, and KLK15, chromosome 19: 56022744–56073589) and prostate cancer risk in 1,172 prostate cancer cases and 1,157 PSA screened controls in men of European ancestry from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial5,6, in which serum PSA was used in screening for this disease. We also examined the prostate cancer risk relationship for 12 of these tagSNPs in the KLK3 region (chromosome 19: 56031744–56063231) in four independent studies including 4,020 prostate cancer cases and 4,028 controls (American Cancer Society Cancer Prevention Study II, the Health Professionals Follow-up Study, the CeRePP French Prostate Case-Control Study, and the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study)6, as a component of the Cancer Genetic Markers of Susceptibility (CGEMS)-GWAS6 (http://cgems.cancer.gov; Supplementary Methods).

None of the 24 KLK-region tagSNPs showed strong evidence for association with prostate cancer in PLCO (Table 1: Cases vs Controls in PLCO) and none of the 12 KLK3-region SNPs was significant in the CGEMS combined analyses (Table 1: Cases vs Controls in CGEMS combined). No substantial differences in risk were noted by disease aggressiveness (Supplement Table 1). Two tagSNPs (rs1058205 and rs2735839), located in the 3′ untranslated region of KLK3, in high linkage disequilibrium (LD; r2=0.8; Figure 1), along with four variants 8–23 kb upstream of the gene (rs2659056, rs2569729, rs266849, and rs266870) and several variants about 7 kb downstream (rs1506684 and rs2569739, in high LD, r2=1.0), were associated with strong differentials in serum PSA concentrations (e.g., rs2735839, p trend=4.1×10−9; Table 1, Adjusted Mean PSA Level, and Figure 1-Panel A). However, when these SNPs were simultaneously included in the multivariate model, associations remained for rs2735839, but others were no longer significantly associated with PSA concentrations.

Figure 1
Associations of tagSNPs in the KLK region with PSA concentrations and prostate cancer risk in the PLCO Trial
Table 1
Associations of tagSNPs in the KLK region with prostate cancer risk and PSA concentrations in the PLCO Cancer Screening Trial and with prostate cancer in the combined CGEMS follow-up study.

Eeles et al 1 reported strong associations between three KLK3 SNPs (p-values for stage 1 were 1.2×10−7, 1.0×10−16 and 2.4×10−20 for rs2659056, rs266849, and rs2735839) and prostate cancer, in a GWAS, where controls were selected by design for low PSA (<0.5 ng/ml) and no limitations were placed on case-group PSA values. The replications in non-PSA selected groups showed attenuated associations (p-values for stage 2 were 0.424, 0.228 and 0.0002, respectively). Pal et al 2 also reported a strong association of prostate cancer with KLK3 variants, where control subjects were also preferentially selected by PSA levels (< 2.5 ng/ml). When we preferentially limited the men in the control group in the PLCO Trial GWAS to those with PSA <0.5 ng/ml, as an exercise, we show prostate cancer risk associations (Figure 1-Panel B [[filled triangle]] and Supplement Table 2) greater than 5-fold for some genotypes (rs1058205, OR=0.19, 95%CI=0.10–0.36, p=0.000015), whereas the same SNPs showed no clear association when the full control group was employed (Figure 1-Panel B [●] and Table 1). Furthermore, modest KLK3 associations with prostate cancer risk observed in our full case-control series and in other studies where controls are not selected by design for PSA level3 may still be related to PSA-based case ascertainment, because PSA is widely used as a clinical aid in selecting men for biopsy for suspect prostate cancer. In PLCO, KLK SNPs were also not associated with prostate cancer when only cases and controls with high PSA levels or only cases and controls with low PSA levels were compared (Supplement Table 3). Thus, the observed associations between the KLK SNPs and prostate cancer risk in earlier studies4,5,3 and in our exercise in PLCO may be due to selection for PSA differentials and not causally related to underlying disease risk.

PSA is a serine protease, functioning in the liquefaction of seminal coagulum7; consistent with our data, Pal et al2 showed serum PSA associations with rs266849 and rs1058205, and Cramer et al4 showed that two SNPs in the 5′ region of KLK3 are related to increased KLK3 promoter activity and serum PSA level. In our study, the association with PSA was strongest with rs2735839, which is highly correlated with rs1058205 (r2=0.8); associations observed with the other SNPs in our study appeared to be largely driven by their linkage disequilibrium with rs2735839. Sliding window haplotype analysis (Supplement Figure 1) and close inspection of the most strongly associated haplotype window (Supplementary Table 4) suggested that additional unmeasured risk variant(s) may influence PSA concentrations.

PSA is an early marker predictive for the presence of prostate cancer and its use has contributed to the near doubling of diagnosed cases over the past two decades in countries where use is common8. While trials are underway to determine whether screening with PSA reduces prostate cancer mortality5,9, it is apparent that many men are diagnosed with clinically indolent cancer on the basis of PSA screening; the over-detection rate is estimated to range from 18 to 56%9,10. In addition, the majority of men with an elevated PSA have a negative biopsy11. In our study, KLK3 variant status was related to PSA test-positivity in control men (Supplementary Table 5). While we show that KLK3 SNPs are not risk factors highly correlated with prostate cancer per se, a combination of KLK3 SNP and serum PSA monitoring, possibly including a broader spectrum of protein and DNA tests12, is a potential tool for advancement in prostate cancer early detection.

In conclusion, SNPs in the KLK3 region were not associated strongly with prostate cancer in large series of cases and controls, where controls are not selected by design for low PSA and even the modest KLK3-prostate cancer risk associations observed in non-selected populations may be due to PSA-directed differential identification of prostate cancer cases with particular KLK3-PSA profiles.

Supplementary Material

supplement

Acknowledgments

The Prostate Lung Colorectal Ovarian Cancer Screening Trial (PLCO) is supported by the Intramural Research Program of the Division of Cancer Epidemiology and Genetics and by contracts from the Division of Cancer Prevention, National Cancer Institute, US National Institutes of Health (NIH), Department of Health and Human Services (DHHS). The Health Professionals Follow-up Study (HPFS) study is supported by NIH grants CA55075 and U01CA098233. The American Cancer Society (ACS) study is supported by U01 CA098710. The Alpha Tocopherol Beta-Carotene Cancer Prevention study (ATBC) Study is supported by the Intramural Research Program of the National Cancer Institute, NIH, and by US Public Health Service contracts N01-CN-45165, N01-RC-45035, and N01-RC-37004 from the National Cancer Institute, NIH, DHHS. A.S.K is supported by RO1CA112028. Centre de Recherche pour les Pathologies Prostatiques (CeRePP) is grateful to J.P.B. and Generali for their charitable donations to this project. The genome wide scans have been supported by the National Cancer Institute, National Institutes of Health, under contract N01-CO-12400. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government.

Notes

This is a commentary on article Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK, Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, Field HI, Southey MC, Severi G, Donovan JL, Hamdy FC, Dearnaley DP, Muir KR, Smith C, Bagnato M, Ardern-Jones AT, Hall AL, O'Brien LT, Gehr-Swain BN, Wilkinson RA, Cox A, Lewis S, Brown PM, Jhavar SG, Tymrakiewicz M, Lophatananon A, Bryant SL; UK Genetic Prostate Cancer Study Collaborators; British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators, Horwich A, Huddart RA, Khoo VS, Parker CC, Woodhouse CJ, Thompson A, Christmas T, Ogden C, Fisher C, Jamieson C, Cooper CS, English DR, Hopper JL, Neal DE, Easton DF Multiple newly identified loci associated with prostate cancer susceptibility.. Nat Genet. 2008;40(3):316-21.

References

1. Eeles RA, et al. Nat Genet. 2008;40:316–21. [PubMed]
2. Pal P, et al. Hum Genet. 2007;122:251–259. [PubMed]
3. Lai J, et al. Carcinogenesis. 2007;28:1032–1039. [PubMed]
4. Cramer SD, et al. J Natl Cancer Inst. 2003;95:1044–1053. [PubMed]
5. Prorok PC, et al. Control Clin Trials. 2000;21:273S–309S. [PubMed]
6. Thomas G, et al. 2008;40:310–5. [PubMed]
7. Borgono CA, et al. Mol Cancer Res. 2004;2:257–280. [PubMed]
8. Woolf SH. N Engl J Med. 1995;333:1401–1405. [PubMed]
9. Draisma G, et al. J Natl Cancer Inst. 2003;95:868–878. [PubMed]
10. Etzioni R, et al. J Natl Cancer Inst. 2002;94:981–990. [PubMed]
11. Presti JC, Jr, et al. J Urol. 2003;169:125–129. [PubMed]
12. Nam RK, et al. J Clin Oncol. 2003;21:2312–2319. [PubMed]